April 13, 2020

Shrimp Disease Diagnostics Market Worth Will Reach US$ XX Mn According To Forecast By 2029

Cultured shrimps or farm-grown shrimps are considered for diagnostic tests, and the shrimp disease diagnostics comprise of reagents and kits that are used to diagnose viral diseases in shrimps. The global market for shrimp disease diagnostics registered revenues worth US$ 360 Mn in the year 2018, according to a recent research study of Persistence Market Research (PMR).

The shrimp disease diagnostics market has been analysed across the regions of North America, Latin America, Europe, East Asia, South Asia, Oceania, MEA and Emerging Countries such as China, Thailand and India. Due to the high viral-borne endemic shrimp diseases, countries such as China, Thailand, and India are estimated to be the fastest-growing regional markets for shrimp disease diagnostics, and are poised to offer significant opportunities.

With a large number of ongoing research initiatives pertaining to shrimp disease, the demand for shrimp disease diagnostics is estimated to grow significantly over the forecast period. Moreover, mergers & acquisitions and research-based collaboration agreements by key manufacturers in the shrimp disease diagnostics market are also among factors estimated to fuel the growth of the market.

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/29626

Assay-based Kits Remain High Selling

The market for shrimp disease diagnostics comprises of assay-based kits and rapid testing kits. Assay-based kits are used for qualitatively assessing and quantitatively measuring the amount or functional activity of a target entity (shrimp virus) in a sample. Rapid tests are tailored during the preliminary screening of a target entity, and are very useful in resource-limited settings. Rapid tests produce results of high quality and are easy to perform with a quick output (10 minutes to 2 hours).

Rapid tests are based on agglutination and many immunological techniques. According to PMR, assay-based kits are expected to hold a prominent position in the global shrimp disease diagnostics market, as compared to reagent kits, in terms of revenue with a global market share of about 60% in 2019.

Over the years, shrimp disease diagnostic products have become attractive assay kits as compared to manual assays. The increased demand for shrimp disease diagnostics reagent kits can be attributed to their accuracy, high throughput, and reliable results, which can be achieved in a fraction of the time. Furthermore, the emergence of third-generation DNA-based diagnostic tools have also revolutionized the shrimp disease diagnostics market for quick disease diagnosis. Many studies on the efficacy comparison of manual and shrimp disease diagnostics reagent kits have shown that the latter provides high-throughput results with a high rate of accuracy and reproducibility.

Major players in the shrimp disease diagnostics market are concentrating their efforts on investing in research and development as well as to introduce new kit-based products into the market, which are not only more affordable, but also reliable for small pathology testing laboratories. In addition, several technological advancements in molecular-based diagnostics are currently under development, which will find applications in a wide range of marine and aquaculture-based studies.

For Critical Insights On The Shrimp Disease Diagnostics Market, Request For Customization Here @ https://www.persistencemarketresearch.com/request-customization/29626

Aquaculture Farming Picking Pace in Developing Countries

Macro-economic factors, such as favorable government regulations and policies for start-up companies to set up their manufacturing hubs, are estimated to fuel the growth of the shrimp disease diagnostics market. Moreover, increase in the number of aquaculture and marine laboratories is also expected to boost the demand for shrimp disease diagnostics. Furthermore, the growth of the healthcare sector as well as aquaculture farming in emerging nations is also estimated to fuel the growth of the shrimp disease diagnostics market. For instance, according to the World Bank, in 2016, China’s healthcare expenditure was 4.9% of the GDP, and it is anticipated to double by 2020.

The shrimp disease diagnostics market report offers a comprehensive taxonomy of the shrimp disease diagnostics market based on the reagents kit, disease type, end user, and region. Based on the reagents kit type, the global shrimp disease diagnostics market is segmented into rapid testing kits and assay-based kits.

Based on disease type, the shrimp disease diagnostics market is further classified White Spot Syndrome Virus (WSSV ), Taura Syndrome Virus (TSV), Yellow Head/Gill Associated Virus (YHV/GAV), Infectious Hypodermal and Hematopoietic Virus (IHHNV), Hepatopancreatic Parvovirus (HPV), Monodon Baculovirus (MBV), Infectious Myonecrosis Virus (IMNV), Necrotising Hepatopancreatitis Bacteria (NHP-B), Mourilyan Virus (MoV) and Early Mortality Syndrome (EMS). With so many viral-borne shrimp diseases and opportunities, the shrimp disease diagnostics market also offers significant potential for small and emerging players to invest in the market.

For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/29626

Company Profile

  • HiMedia Laboratories
  • Speedy Assay Sdn Bhd
  • REAGEN LLC
  • FUJIKURA KASEI CO., LTD.
  • GeneReach Biotechnology Corp.
  • Thermo Fisher Scientific
  • Lab – Ind Resource Sdn Bhd.
  • SUREBIO
  • Auro Biotechnologies

More About the Report –

Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.

The advent of health information technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor-neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Molecular Diagnostics Market –

Molecular Diagnostics Market Segmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.

Next-Generation Sequencing Market –

Next Generation Sequencing Market Segmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.

Ophthalmology devises Market –

Ophthalmology devises Market Segmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.

Intravenous Iron Drugs Market –

Intravenous (IV) Iron Drugs Market Segmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., and Sanofi.

Syndromes Progressive Ataxia Weakness Disorders Market –

Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Market Segmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

305 Broadway, 7th Floor
New York City, NY 10007
United States
Ph.no. +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com
Website: https://www.persistencemarketresearch.com